Carmell (CTCX) Competitors $5.70 +3.06 (+115.50%) As of 07/15/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTCX vs. CV, MGRM, SKIN, CVRX, TLSI, INGN, SGHT, PROF, ELMD, and LNSRShould you be buying Carmell stock or one of its competitors? The main competitors of Carmell include CapsoVision (CV), Monogram Orthopaedics (MGRM), Beauty Health (SKIN), CVRx (CVRX), TriSalus Life Sciences (TLSI), Inogen (INGN), Sight Sciences (SGHT), Profound Medical (PROF), Electromed (ELMD), and LENSAR (LNSR). These companies are all part of the "medical equipment" industry. Carmell vs. Its Competitors CapsoVision Monogram Orthopaedics Beauty Health CVRx TriSalus Life Sciences Inogen Sight Sciences Profound Medical Electromed LENSAR Carmell (NASDAQ:CTCX) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations. Which has preferable earnings & valuation, CTCX or CV? CapsoVision has lower revenue, but higher earnings than Carmell. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarmell$32.84K3,628.57-$15.44MN/AN/ACapsoVisionN/AN/AN/AN/AN/A Do institutionals & insiders believe in CTCX or CV? 24.2% of Carmell shares are owned by institutional investors. 29.0% of Carmell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is CTCX or CV more profitable? CapsoVision's return on equity of 0.00% beat Carmell's return on equity.Company Net Margins Return on Equity Return on Assets CarmellN/A -217.50% -50.22% CapsoVision N/A N/A N/A Does the media refer more to CTCX or CV? In the previous week, CapsoVision had 2 more articles in the media than Carmell. MarketBeat recorded 2 mentions for CapsoVision and 0 mentions for Carmell. Carmell's average media sentiment score of 0.00 beat CapsoVision's score of -0.50 indicating that Carmell is being referred to more favorably in the media. Company Overall Sentiment Carmell Neutral CapsoVision Negative SummaryCarmell beats CapsoVision on 4 of the 7 factors compared between the two stocks. Get Carmell News Delivered to You Automatically Sign up to receive the latest news and ratings for CTCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTCX vs. The Competition Export to ExcelMetricCarmellSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.16M$68.57M$5.51B$9.39BDividend YieldN/AN/A4.25%4.09%P/E RatioN/A5.3528.2719.87Price / Sales3,628.57204.67424.8998.56Price / CashN/A18.4135.5357.53Price / Book5.337.518.215.70Net Income-$15.44M-$25.04M$3.24B$257.71M7 Day Performance142.55%5.88%0.43%0.89%1 Month Performance134.57%1.68%7.84%11.09%1 Year Performance307.14%39.94%28.19%16.58% Carmell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTCXCarmellN/A$5.70+115.5%N/A+275.0%$119.16M$32.84K0.0014Gap UpHigh Trading VolumeCVCapsoVisionN/A$4.59+5.0%N/AN/A$212.70MN/A0.0090MGRMMonogram Orthopaedics1.0329 of 5 stars$5.90+0.5%$5.40-8.5%+161.5%$210.56MN/A-13.1128High Trading VolumeSKINBeauty Health0.2831 of 5 stars$1.64-12.3%$1.42-13.6%-21.8%$206.63M$322.47M-4.001,030CVRXCVRx3.0618 of 5 stars$7.10-3.4%$14.50+104.2%-14.7%$185.12M$52.87M-3.26160News CoveragePositive NewsTLSITriSalus Life Sciences2.9987 of 5 stars$4.74-4.8%$10.75+126.8%-12.8%$179.36M$32.14M-4.23106Positive NewsINGNInogen4.2651 of 5 stars$6.55-2.4%$11.00+67.9%-32.9%$176.11M$339.96M-5.701,030News CoverageSGHTSight Sciences1.5753 of 5 stars$3.34-9.7%$3.93+17.8%-57.8%$172.67M$78.11M-3.41210Analyst ForecastPROFProfound Medical2.8938 of 5 stars$5.70-0.9%$11.50+101.8%-40.6%$171.29M$10.68M-4.67150News CoveragePositive NewsELMDElectromed0.861 of 5 stars$18.24-5.5%$38.00+108.3%+20.1%$152.96M$61.44M24.32160LNSRLENSAR1.2919 of 5 stars$12.90flat$15.00+16.3%+156.6%$152.09M$53.49M-2.66110Positive News Related Companies and Tools Related Companies CV Alternatives MGRM Alternatives SKIN Alternatives CVRX Alternatives TLSI Alternatives INGN Alternatives SGHT Alternatives PROF Alternatives ELMD Alternatives LNSR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTCX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carmell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carmell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.